Table 1 Clinicopathological characteristics of the patient cohorts
From: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma
Characteristic | Low expression of SLC10A3 | High expression of SLC10A3 | P-value |
|---|---|---|---|
n | 322 | 322 | Â |
T stage, n (%) | Â | Â | 0.817 |
 T1 | 11 (1.7%) | 9 (1.4%) |  |
 T2 | 58 (9%) | 53 (8.3%) |  |
 T3 | 216 (33.7%) | 220 (34.3%) |  |
 T4 | 34 (5.3%) | 40 (6.2%) |  |
N stage, n (%) | Â | Â | 0.006 |
 N0 | 203 (31.7%) | 165 (25.8%) |  |
 N1 | 63 (9.8%) | 90 (14.1%) |  |
 N2 | 53 (8.3%) | 66 (10.3%) |  |
M stage, n (%) |  |  |  < 0.001 |
 M0 | 249 (44.1%) | 226 (40.1%) |  |
 M1 | 29 (5.1%) | 60 (10.6%) |  |
 Age, median (IQR) | 69 (59, 77) | 66 (57, 75) | 0.049 |